The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
A. Inoue
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Sanofi
K. Kobayashi
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Janssen-Ortho; Lilly; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Nippon Kayaku; Novartis; Taiho Pharmaceutical; Yakult
M. Maemondo
Honoraria - Chugai Pharma; Lilly
S. Sugawara
No relevant relationships to disclose
S. Oizumi
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
H. Isobe
Honoraria - AstraZeneca; Chugai Pharma; Yakult
A. Gemma
Consultant or Advisory Role - Bayer (U); Chugai Pharma (U); Janssen-Ortho (U); Merck (U); Taiho Pharmaceutical (U)
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly
Research Funding - AstraZeneca; GlaxoSmithKline
Y. Saijo
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Sanofi ; Taiho Pharmaceutical; Takeda
H. Yoshizawa
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
K. Hagiwara
No relevant relationships to disclose
T. Nukiwa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly
Research Funding - AstraZeneca; Daiichi Sankyo; Lilly